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Background: Survivin is overexpressed in cancer cells and plays a crucial role in apoptosis evasion. YM155, a
small-molecule inhibitor of survivin, could enhance the cytotoxicity of various DNA-damaging agents. Here, we
evaluated the radiosensitizaion potential of YM155 in human esophageal squamous cell carcinoma (ESCC).
Methods: Cell viability was determined by CCK8 assay. The radiosensitization effect of YM155 was evaluated by
clonogenic survival and progression of tumor xenograft. Cell cycle progression was determined by flow
cytometric analysis. Radiation-induced DNA double strand break (DSB) and homologous recombination repair
(HRR) were detected by the staining of γ-H2AX and RAD51, respectively. Expression of survivin and cell cycle regulators
was detected by Western blot analysis.
Results: YM155 induced radiosensitization in ESCC cell lines Eca109 and TE13, associated with the abrogation of
radiation induced G2/M checkpoint, impaired Rad51 focus formation, and the prolongation of γ-H2AX signaling. G2/M
transition markers, including the activation of cyclinB1/Cdc2 kinase and the suppression of Cdc2 Thr14/Tyr15
phosphorylation were induced by YM155 in irradiated cells. The combination of YM155 plus irradiation delayed
the growth of ESCC tumor xenografts to a greater extent compared with either treatment modality alone.
Conclusions: Our findings suggest that the abrogation of G2 checkpoint and the inhibition of HRR contribute to
radiosensitization by YM155 in ESCC cells.
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Survivin is the smallest member of the inhibitor of apop-
tosis protein (IAP) family with a molecular mass of 16.5
kD. Survivin functions to inhibit mitochondrial pathway
of apoptosis and regulate cell division as a component of
the spindle checkpoint machinery [1]. Overexpression of
survivin was detected in many types of cancers including* Correspondence: sunxcsci@163.com
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unless otherwise stated.esophageal squamous cell carcinoma (ESCC) but rarely
in normal differentiated adult tissues [2-4]. Furthermore,
elevated levels of survivin have been associated with
poor prognosis in several human cancers [5-9]. In ESCC
patients high levels of survivin expression indicated poor
prognosis as well as high resistance to radiotherapy and
chemotherapy [10,11]. Accordingly, the suppression of
survivin expression with the use of antisense oligonucle-
otides or ribozymes effectively overcame apoptosis re-
sistance in different types of cancer cells and sensitized
cancer cells to radiation and chemotherapeutic agents
in vitro and in vivo [12-16].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 YM155 suppresses survivin expression in a dose
dependent manner in human ESCC cells. Eca109 and TE13 cells
were treated with 1, 5, 10, 25, or 50 nmol/L YM155, or DMSO as
control for 48 h. Protein expression levels of IAP family members
were determined by Western blot analysis. GAPDH was used as
loading control.
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primarily through the suppression of apoptosis-related
cell death via direct inhibition of caspase-related pro-
teins. However, it has become increasingly clear that the
role of survivin in response to ionizing radiation far ex-
ceeds a simple inhibition of apoptotic pathway. The
underlying molecular mechanisms seem to be multifa-
ceted and involve broader cellular adaptation processes
within separate subcellular compartments. Chakravarti
et al. are the first to report on novel caspase-independent
mechanisms through which survivin enhances tumor cell
survival upon radiation exposure, including the regulation
of double-strand DNA break repair and cell metabolism
[12]. Recently, Reichert et al. found a direct relationship
between survivin and components of the DNA-double
strand break (DSB) repair machinery following irradiation
in radiation resistant glioblastoma cells [17].
In the nucleus, survivin is selectively expressed at G2/M
phase of the cell cycle and localized to microtubules of the
mitotic spindle, thus performing the role of the regulator
of cell division [18]. Connor et al. showed that survivin
underwent cell cycle-dependent phosphorylation on
Thr34 by a Cdc2/cyclin B1 complex, which was required
to prevent from caspase-9-dependent apoptosis of cells
traversing mitosis and preserve cell viability at cell division
[19]. Thus we speculated that the attenuation of survivin
expression is expected to impact DNA damage induced
G2/M checkpoint.
YM155 was identified as a first-in-class small molecule
inhibitor of survivin. YM155 selectively inhibited survi-
vin expression at both mRNA and protein levels at sub-
nanomolar range and exhibited anticancer activity in
preclinical models of several types of cancers [20-22].
However, the effectiveness of YM155 with ESCC has not
been confirmed. In the present study, we employed two
ESCC cell lines Eca109 and TE-13 to evaluate the radio-
sensitizing effects of YM155 on ESCC, with a special
emphasis on its interference with cell cycle checkpoint.
Results
YM155 selectively reduced the expression of survivin in
ESCC cells
First, we assessed the effect of YM155 on survivin
expression in two ESCC cell lines Eca109 and TE13.
Western blot analysis showed that YM155 inhibited sur-
vivin expression in a dose dependent manner, but had
no significant effect on the abundance of other IAP fam-
ily members such as XIAP and c-IAP1 (Figure 1). These
results suggest that YM155 specifically suppresses survi-
vin at low nanomolar concentrations in ESCC cells.
YM155 enhanced cytotoxicity of irradiation in ESCC cells
Next, we evaluated the viability of ESCC cells after 24-
and 48- h incubation with increasing concentration ofYM155. At 24 h, the IC50 of YM155 on Eca109 and
TE13 cells were 21 and 60 nM, respectively. At 48 h,
the IC50 of YM155 on Eca109 and TE13 cell lines were
12 and 50 nM, respectively (Figure 2A). The sub-toxic
concentrations of YM155 (5 nM and 10 nM) were
adopted to investigate the radiosensitivity of the two
cell lines.
Colony-forming assay with ESCC cells showed that
YM155 promoted radiation-induced clonogenic cell
death in a dose dependent manner. When the
concentration of YM155 reached 10 nM, the SER
(sensitization enhancement ratio) of Eca109 and TE13
cells was 1.51 and 1.73, respectively. Radiobiological
variables were calculated and summarized in Table 1.
These data indicate that YM155 remarkably enhanced
cell death in irradiated ESCC cells.
YM155 reduced irradiation induced accumulation of G2/M
fraction in ESCC cells
To explore the effect of survivin inhibitor on radiation-
induced cell cycle checkpoint, we performed cytometric
analysis on ESCC cells exposed to 8 Gy of X rays. The
results showed that both two cell lines were arrested in
G2 phase of cell cycle (62.5% for Eca109 and 66.1% for
TE13). Radiation-induced G2/M arrest was abrogated
by 10 nM YM155 (34.7% for Eca109 and 36.4% for
TE13), with a concomitant rise in G1 and S phases
(Figure 3A and B). Exposure of the cells to YM155
alone caused small decrease in G2/M fraction and slight
accumulation of G1 population (Figure 3A). In order to
confirm that YM155 abrogated G2 arrest, rather than
induced a G1/S- phase block, mitotic inhibitor nocodazole
was used. As shown in Figure 3B, the addition of nocoda-
zole (0.4 μg/mL) successfully prevented irradiated cells ex-
posed to YM155 from cell cycle progression. Therefore,
YM155 seems to impact the progression of cells from G2
to M phase. Detailed data of cell cycle distribution were
summarized in Table 2.
Figure 2 YM155 sensitizes ESCC cells to irradiation. A, ESCC cell lines Eca109 and TE13 were seeded in 96-well plates in triplicate and treated
with various concentrations of YM155 for 24 or 48 h. Cell viability was determined by CCK8 assay. * and #, P < 0.05 versus control. B, Cell survival
curve was established by clonogenic survival assay. The cells were treated with 5 nM or 10 nM YM155 and ionizing radiation as illustrated and
harvested after incubation for 10–14 d. Each bar represented mean ± SE from 3 independent experiments. * and #, P < 0.05 versus control; ** and
##, P < 0.01 versus control.
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cyclin B1 expression in irradiated ESCC cells
Histone H1 kinase activity of Cdc2 was suppressed in
irradiated Eca109 cells. However, YM155 resulted in
significant activation of Cdc2 kinase in irradiated
cells, and this effect was most evident when noco-
dazole was administered post-irradiation to prevent
cells from existing M phase (Figure 4A). Cdc2/cyclin
B1 complex is the key enzyme regulating G2 to M
transition and is controlled by the phosphorylation
at various sites. DNA damage induced G2 phase arrest
is linked to the accumulation of relatively inactive,Table 1 Radiosensitization effects of YM155 on ESCC cells in
D0 (Mean inactivation dose) Dq
Eca109
Control 2.74 1.78
YM155 (5 nM) 2.34 0.13
YM155 (10 nM) 1.82 0.03
TE13
Control 1.52 1.97
YM155 (5 nM) 0.98 1.41
YM155 (10 nM) 0.88 0.82hyperphosphorylated Cdc2/cyclin B1 complexes which
have inhibitory phosphates on two residues (Thr14/
Tyr15) of Cdc2. To determine whether YM155 in-
duced abrogation of G2 checkpoint is mediated by the
suppression of Cdc2 inhibitory phosphorylation, we
monitored the phosphorylation level of Cdc2 as well
as cyclin B1 expression in Eca109 and TE13 cells.
Western blot analysis showed that treatment with
YM155 alone slightly suppressed basal level of
phospho-Cdc2 and cyclin B1. In both ESCC cell lines,
irradiation induced inhibitory phosphorylation of
Cdc2 on T-14 and Y-15 and accumulation of cyclinvitro







Figure 3 YM155 abrogates radiation-induced G2 arrest in ESCC cells. A. Eca109 and TE13 cells were treated with YM155, X ray or the
combination modality and then harvested for analysis of cell cycle distribution by flow cytometry. B. Cells treated with X ray alone or in
combination with YM155 were then incubated in the absence (left panels) or the presence (right panels) of nocodazole (NOC, 0.4 μg/mL) for
24 h. Shown were representative flow cytometry plots of three experiments with similar results.
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48 h for TE13. YM155 evidently abrogated X-ray
induced Cdc2 hyperphosphorylation and cyclin B1 ac-
cumulation without affecting total Cdc2 and phospho-
Cdc25C protein levels (Figure 4B).YM155 inhibited irradiation induced homologous
recombination repair (HRR)
To further explore the mechanisms of YM155 induced
abrogation of G2 arrest, we detected γ-H2AX and
RAD51 foci in Eca109 cells. As anticipated, radiation
Table 2 Abrogation of G2/M checkpoint by YM155 in ESCC cells
Eca109 TE13
Treatment G1 (%) S (%) G2/M (%) G1 (%) S (%) G2/M (%)
Control 42.7 26.3 28.0 45.7 27.4 23.9
YM155 51.4 22.2 22.6 59.6 35 7.8
IR 13.6 23.1 62.5 23.4 8.7 66.8
IR + YM155 45.8 14.3 34.7 46.6 13.2 36.4
Treatment G1 (%) S (%) G2/M (%) G1 (%) S (%) G2/M (%)
Control 42.1 43.3 13.9 39.7 39.9 18.7
IR 12.4 25.1 60.0 32.9 21.4 46.0
IR + Noc 2.6 10.8 84.5 5.4 18.8 73.0
IR + YM155 36.8 31.2 28.9 43.5 18.2 35.9
IR + YM155 + Noc 20.7 36.0 41.4 32.1 11.2 55.9
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was reduced to basal level 24 h post irradiation (data not
shown). However, YM155 treatment resulted in a signifi-
cant prolongation of γ-H2AX signal at least 24 h post
irradiation (47.7 ± 3.0%) compared with radiation alone
(7 ± 2.8%; P < 0.001) (Figure 5A). These results suggest
that YM155 significantly inhibited the repair of DSBs
manifested as the persistence of γ-H2AX foci at 4 to
24 h after radiation. We next assessed RAD51 focus for-
mation, as a hallmark of ongoing DNA homologous re-
combination repair (HRR). In response to radiation
alone, Rad51 formed discrete nuclear foci at 8 h and the
percentage of RAD51 foci-positive cells increased up to
36 h after treatment. However, in the presence of
YM155, the assembly of Rad51 foci in response to radi-
ation was significantly suppressed, which was in contrast
with kinetics of γ-H2AX (Figure 5B). Taken together,
these findings support the conclusion that YM155 in-
hibits HRR, likely through the inhibition of Rad51 focus
formation in response to radiation.
YM155 enhanced caspase-associated apoptosis in irradiated
ESCC cells
To analyze the possible enhancement of radiation-
induced apoptosis in ECSS cells after YM155 exposure,
we first performed Annexin V/FITC and propidium
iodide dual staining to quantify apoptotic cells after
treatment with YM155 (10 nM) and radiation (8 Gy),
alone and in combination for 48 h. As shown in Figure 6A,
the induction of early apoptotic events (Annexin V posi-
tive) was most evident when cells were treated with
8 Gy plus YM155. The difference between groups of
combinational and each single treatment was statisti-
cally significant (P < 0.01) in both Eca109 and TE13
cells. We next detected the cleavage of caspase-3 and
PARP. As shown in Figure 6B, higher levels of cleaved
PARP and caspase-3 were observed in Eca109 cells
treated with 8 Gy radiation plus 10 nM YM155,compared with the cells treated with YM155 or radi-
ation alone. Similar results were observed in TE13 cells.
YM155 inhibited survivin expression and radiosensitized
Eca109 in vivo xenograft tumor
To determine the in vivo radiosensitizing activity of
YM155 for ESCC, mice bearing Eca109 cells xenograft
tumor were utilized. As shown in Figure 7A, YM155 or
irradiation alone produced significant tumor volume re-
gression on day 20 (P = 0.006 for irradiation, P = 0.001
for YM155) compared to control group. However, the
combination of YM155 and radiation produced more
tumor volume regression (P < 0.05 for YM155 plus IR
versus single treatment). Notably, the combined treat-
ment significantly prolonged the time required for
tumor volume doubling relative to radiation or YM155
alone (11.9 d vs. 2.3 or 3.3 d). No complete regression in
either treatment alone was observed. The enhancement
factor (EF) was 3.75. The tumor growth delay induced
by each modality was summarized in Table 3. All kinds
of the treatments were well tolerated by the animals with
no evidence of local cutaneous damage or systemic tox-
icity such as weight loss (Figure 7B).
Immunohistochemical analysis demonstrated that
YM155 significantly inhibited survivin expression in ei-
ther IR treated or untreated tumors (Figure 7C, upper
panel). The mean density of survivin staining in tumors
from YM155 treated groups (YM155: 0.021 ± 0.0087; IR
plus YM155: 0.008 ± 0.0036) was significantly lower than
that in YM155 untreated groups (Control, 0.061 ±
0.0025; IR: 0.050 ± 0.0044) (P < 0.01). The TUNEL assay
was performed to quantify apoptosis in tumor sections
from different groups. As shown in Figure 7C (middle
panel), the mean apoptotic index was 2.8% in the control
group, 30.6% in the YM155 group, and 22.2% in the IR
group; while the combined treatment group had an
apoptotic index of 61.2%, significantly higher than either
treatment alone (P < 0.01). Furthermore, we performed
Figure 4 YM155 potentiates the activation of Cdc2 kinase and suppresses protein expression related to G2/M checkpoint. A. Irradiated
Eca109 cells were treated with YM155 in the absence or the presence of nocodazole. Cdc2 was immunoprecipitated using Cdc2 antibody and
Cdc2 kinase activity was measured by Histone H1 kinase assay described. The relative Cdc2 kinase activity was shown in the histogram (right)
(*, P < 0.05; **, P < 0.01). B. Eca109 and TE13 cells were treated with YM155, X ray or the combination modality and subjected to Western blot
analysis of G2/M checkpoint related proteins phospho-Cdc2, Cdc2, cyclin B1, phospho-Cdc25C.
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shown in Figure 7C (lower panel), 57.1% cells were posi-
tive for cleaved caspase-3 staining in combined treat-
ment group, compared to 31.2% in YM155 alone group
and 10.8% in IR alone group. These data indicated that
YM155 radiosensitized ESCC in vivo.
Discussion
In the present study, we have shown that survivin inhib-
ition by YM155 enhanced radiation-induced inhibition
of growth of esophageal cancer cells and xenografts.
Radiosensitization by YM155 in ESCC is associated with
the abrogation of radiation-induced G2 checkpoint as
well as the attenuation of homologous-recombination-
mediated DNA damage repair.
Iwasa et al. indicated that radiosensitization of NSCLC
cells by YM155 was associated with increased activity of
caspase-3, suggesting that YM155 sensitized tumor cells
to radiation partly by enhancing radiation-induced apop-
tosis [23]. Our findings now show that abrogation of G2
checkpoint in response to radiation is an additional mech-
anism of sensitization by survivin inhibitor in esophageal
cancer cells. We found that YM155 at nanomolar concen-
tration was sufficient to abrogate G2 arrest. It is known
that shortening of the G2 checkpoint leads to decreased
repair of radiation-induced damage that could take place
before cell division [24,25]. In support of this possibility,
we found that YM155 significantly increased persistent γ-
H2AX expression and suppressed RAD51 recruitment inthe nuclei of irradiated ESCC cells. The impairment in
DSB repair could enhance the apoptosis induced by irradi-
ation. Consistently, we demonstrated that YM155 en-
hanced the apoptosis and promoted the cleavage of
caspase-3 and PARP in irradiated ESCC cells.
For the radiosensitization of cancer cells, pharmaco-
logical agents with the ability to inhibit specific check-
point components, particularly at the G2/M transition,
have gained interest recently. UCN-01, AZD7762 and
SB-218078 have demonstrated synergy with ionizing ra-
diation to inhibit cancer growth by abrogating G2/M
checkpoint through selective inhibition of Chk1 [26-28].
Caffeine and pentoxifylline were radiosensitizers that
disrupted radiation-induced G2/M checkpoint by inhibit-
ing the activation of ATM and ATR [9,11]. DNA damage
induced G1/S arrest and subsequent Non-homologous
end joining (NHEJ) repair are p53-dependent and, thus,
are deficient in many tumor cells [29]. Wang et al.
showed that UCN-01 was much less active in abrogating
γ-ray-induced G2 checkpoint in MCF-7 cells that had
normal p53 function, but it preferentially increased the
cytotoxicity of cisplatin in MCF-7 cells defective for p53
function [28]. In addition, Chk1 inhibition preferentially
sensitizes HCT116 p53−/− cells (versus HCT p53+/+) to
gemcitabine and radiation [30,31]. Therefore, the cells
harboring mutations in p53 are deficient in G1 check-
point and depend on p53-independent G2 checkpoint
for DNA damage repair, rendering them more sensitive
to G2 checkpoint abrogation [32]. Similarly, in this study
Figure 5 YM155 suppresses radiation-induced DSB repair in ESCC cells. A. YM155 led to significant increase in γ-H2AX staining. B. YM155
inhibited the formation of radiation-induced Rad51 foci. Eca109 cells were treated with 0.1% DMSO or 10 nM YM155 and then exposed to 4 Gy
of X ray. After incubation for the indicated times, the cells were fixed for immunofluorescence detection of γ-H2AX (green) and Rad51 (red) foci.
Representative images of nuclei (blue) and foci were shown (left lane), scale bar, 10 μm. Data were expressed as the percentage of cells staining
positive for foci and plotted as the mean SEM of 3 independent experiments (right lane). Nuclei containing ≥10 immunoreactive foci were scored
as positive for γ-H2AX, and ≥5 foci as positive for RAD51. At least 100 nuclei were counted for each experiment. * and #, P < 0.05; **, P < 0.01.
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both ESCC cell lines, indicating aberrant function of p53
in these cell lines. However, further studies are needed
on more types of cells with identified p53 status to
evaluate the influence of p53 function on YM155 medi-
ated abrogation of G2 checkpoint and enhancement of
radiation cytotoxicity.
Although this is the first study demonstrating G2
checkpoint abrogation by a survivin suppressant during
radiosensitization, some efforts have previously been
made to investigate the contribution of survivin inhibition
to cell cycle transition. Transfection of siRNA directed
against survivin caused specific G0/G1 phase arrest in
hepatocellular and lung cancer cells [33,34]. However,
in gastric cancer, survivin-specific siRNA caused cells
accumulation in the G2/M phase and diminished the
number of cells in the G0/G1 phase [35]. Yamanaka
et al. reported that the concomitant treatment of
YM155 relieved docetaxel-induced cell cycle arrest at
the G2/M phase and synergistically enhanced the cyto-
toxic activity of docetaxel [36]. Accordingly, our present
findings demonstrate that YM155 abrogates the G2 ar-
rest induced by ionizing radiation, thus resulting inpreferential cancer cell death. YM155 probably abro-
gates G2 checkpoint by inhibiting the Wee1/Mik1 ki-
nases that suppress Cdc2 activation or by activating the
Cdc25C phosphatase that, in turn, activates Cdc2 [37].
Conclusions
Targeting survivin with potent inhibitor YM155 modu-
lates G2/M cell cycle checkpoint and mediates radio-
sensitization of esophageal cancer cells both in vitro
and in vivo. Our preclinical results identify survivin in-
hibitor YM155 as a novel cell-cycle checkpoint abro-
gator which provides a rationale for future clinical
investigation of therapeutic efficacy of YM155 in com-
bination with DNA-damaging agents. Furthermore,
our findings suggest that the crucial role of survivin in
cell cycle regulation should be investigated in depth in
future studies.
Methods
Cell culture and reagents
The human esophageal squamous cell carcinoma cell
lines Eca109 and TE13 were obtained from Shanghai
Cell Bank (Chinese Academy of Sciences, Shanghai,
Figure 6 YM155 enhances radiation induced apoptosis. Cells were seeded into six-well plates at the concentration of 2 × 105/mL, incubated
with 10 nmol/L YM155 or 0.1% DMSO for 24 h, and (or not) irradiated at dose of 10 Gy, respectively. Forty-eight hours after incubation, cells were
harvested. A, The cells were stained with AnnexinV/FITC and propidium iodide and examined by flow cytometry for apoptotic cell populations.
Data were Mean ± SD (n = 3). **, P < 0.01. B. Western blot analysis of apoptosis-related proteins. Actin was used as a loading control.
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Thermo Scientific, MA) supplemented with 10% fetal
bovine serum (Hyclone) at 37°C under a humidified
atmosphere of 5% CO2. YM155 monobromide was
purchased from SelleckChem (Houston, TX). For the
in vitro experiments, YM155 was dissolved in DMSO
and diluted in medium to a final DMSO concentration
of ≤0.1%. For the in vivo experiments, YM155 was
dissolved and diluted in saline immediately beforeadministration. Mitotic inhibitor nocodazole was pur-
chased from Beyotime institute of biotechnology
(Shanghai, China).
Irradiation conditions
X-ray radiation was delivered by a 6 MV linear acceler-
ator (Elekta, Stockholm, Sweden) at a dose rate of
250 cGy/min with a source-to-target distance of 100 cm.
For tumor irradiation, animals were anesthetized with
Table 3 Radiosensitization effects of YM155 on Eca109 xenograft mouse model
Treatment Doubling time (days) Absolute growth delay (days)a Normalized growth delay (days)b Enhancement factor
Control 5.7 ± 0.5 0
IR 8.0 ± 2.0 2.3 (8.0-5.7)
YM155 9.0 ± 1.6 3.3 (9.0-5.7)
IR + YM155 17.6 ± 6.5 11.9 (17.6-5.7) 8.6 (11.9-3.3) 3.75 (8.6/2.3)
aAbsolute growth delay, the doubling tumor time of treatment group minus that of control group; bNormalized growth delay, the time of absolute growth delay
of tumor in IR combined with YM155 group minus that of YM155 group.
Figure 7 YM155 inhibits Eca109 xenografts in response to radiation. A. Tumor volume was measured at the indicated times after the onset
of treatment. Data were Mean ± SD from six mice per group; *, P < 0.01, versus control; §, P < 0.05, YM155 plus IR group versus single treatment.
B. Mice body weight of different treatments was measured at the indicated times. C. Immunohistochemistry analysis of survivin and cleaved
caspase-3 expression and TUNEL analysis for apoptosis in tumor sections after different treatments. Histograms represented the mean intensity of
survivin staining (left), the percent of apoptotic cells (middle), and the percent of positive staining of cleaved caspase-3 (right). **, P < 0.01.
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of 1.0 × 1.0 cm radiation field, with the rest of mice
shielded from radiation.
Cell viability assay
Cells were seeded in 96-well plates overnight, then treated
with YM155 at various concentrations (0, 1, 2, 5, 8, 10, 25,
50, 100 nmol/L). Twenty-four and forty-eight hours
later, 10 microliters of CCK-8 solution (Cell counting
kit-8, Dojindo Molecular Technologies, Gaithersburg,
MD, USA) was added to each well. Absorbance was de-
termined at 450 nm after 3 hours of incubation. The
viability of cells was calculated as following: Viability =
(ODtest groupODblank group)/(ODcontrol groupODblank group) ×
100 %, and IC50 (half maximal inhibitory concentration)
was calculated from the dose–response curves. All
experiments were repeated in triplicate.
Western blot analysis
Cells were harvested and homogenized in RIPA lysis
buffer and centrifuged at 12,000 rpm for 20 min at 4°C.
Protein concentrations of the supernatants were deter-
mined using BCA Protein Quantification Kit (Vazyme
biotech co., Itd.). Western blot analysis was performed
as previously described [38], using rabbit polyclonal anti-
bodies to human survivin and c-IAP1 (R&D systems, MN),
XIAP and Cyclin B1 (Cell signaling, MA), phosphor-
Cdc25C, Cdc2, phospho-Cdc2, cleaved PARP and cleaved
caspase-3 (Santa Cruz, CA).
Clonogenic survival assay
Exponentially growing cells were trypsinized as single-
cell suspension and diluted serially to appropriate dens-
ities and seeded in triplicate in six-well plates. After cell
adhesion, they were treated with 0.1% DMSO (control)
or YM155 (5 nM or 10 nM) for 24 h, and then subjected
to 0, 2, 4, 6 or 8 Gy X-rays irradiation. The cells were
then washed with PBS, cultured in drug-free medium for
14 days, fixed with methanol, and stained with Giemsa.
Only colonies containing more than 50 cells were
scored. SF (surviving fraction) of each irradiation group
was corrected by the PE (plating efficiency) of the nonir-
radiated control. The cell survival curves were fitted ac-
cording to a multi-target single-hit model and the
survival enhancement ratio (SER) was calculated as the
ratio of the mean inactivation dose in control cells di-
vided by the mean inactivation dose in YM155-treated
cells. The experiment was repeated for three times.
Flow cytometry for cell cycle
Eca109 or TE13 cells were harvested after 24 h or 48 h
treatment with YM155 (10 nM) and/or 8 Gy X rays, re-
spectively. After washing with ice-cold PBS, the cells
were fixed with ice-cold 70% ethanol and stored at −20°Cfor 1 h. Before analysis by flow cytometry, the cells were
washed with PBS, resuspended in a staining solution con-
taining 20 μl RNase A solution and 400 μl propidium iod-
ide staining solution (Vazyme biotech co., Itd). Next, cell
cycle distribution assessment was performed using a
fluorescence-activated cell sorter (BD FACS Calibur).
Cdc2-Associated H1 Kinase assay
A total of 4 × 107 cells were lysed in 400 μl lysis buffer
(50 mM Hepes/NaOH, pH7.4, 150 mM NaCl, 1% Triton
X-100, 1 mM dithiothreitol, protease/phosphatase in-
hibitor cooktail) on ice for 20 min. The cell lysate was
centrifuged at 15,000 rpm for 10 min at 4°C and concen-
tration of protein in the supernatant was determined
using a BCA protein quantification kit (Beyotime,
Shanghai, China). Cellular extracts were cleared by
incubation with protein A or protein G-agarose (Cell
Signaling, MA) for 30 min at 4°C. After centrifuging at
2,500 rpm for 5 min at 4°C, the supernatant was in-
cubated with 4 μg Cdc2 antibody (Cell Signaling, MA)
and 20 μl protein A/G agarose beads for 2 h at 4°C. The
protein-agarose beads and bound immune complexes
were then pelleted by centrifugation and immunopre-
cipitates were washed twice with lysis buffer and twice
with wash buffer (50 mM Hepes/NaOH, pH 7.4, 10 mM
MgCl2, 1 mM dithio-threitol) and then subjected to a
Cdc2 kinase assay using histone H1 peptide (Merck
Millipore, Darmstadt) as a substrate. The immuno-
complex was incubated with 40 μg wash buffer containing
10 μg of histone H1, 10 mM adenosine triphosphate
(ATP) for 10 min at 30°C, and then subjected to immuno-
blotting using phosphoserine/threonine/tyrosine antibody
(Abcam, Cambridge, MA).
Immunofluorescence
Immunfluorescence detection of phospho- H2AX and
RAD51 foci was performed to monitor DNA double-
strand breaks (DSBs) formation and homologous recom-
bination repair (HRR). Cells cultured on coverslips were
treated with 10 nM YM155 and irradiated with a dose
of 4 Gy to assure a discrimination of individual nuclear
foci in immunofluorescence staining. At indicated time
points, the cells were fixed by 4% paraformaldehyde for
20 min at room temperature and permeabilized with 0.1%
Triton X-100 for 10 min at 4°C. After blocking with
Immunol Staining Blocking Buffer (Beyotime, Shanghai,
China) for 1 h at room temperature, cells were incubated
with antibody for phospho-H2AX (Ser139) (Millipore/
Upstate, Temecula, CA) and RAD51 (EMD Millipore,
Billerica, MA) at 4°C overnight, followed by staining
with Fluorescein (FITC)-conjugated goat anti-mouse
IgG (Jackson Immunoresearch, PA) and Rhodamine
(TRITC)-conjugated goat anti-rabbit IgG (Jackson
Immunoresearch, PA) for 1.5 h at room temperature.
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DAPI and mounted in 3 μl of mounting medium
(Beyotime). Three random fields each containing 50
cells were examined at a magnification of ×100 under a
Zeiss LSM5 confocal laser-scanning microscope (Carl
Zeiss, Jena, Germany). Nuclei containing ≥10 immuno-
reactive foci were scored as positive for γ-H2AX, and ≥5
foci as positive for RAD51.
Apoptosis analysis
Annexin V-FITC/PI dual staining was performed by
using apoptosis detection kit from Keygen Biotech
(Nanjing, China) according to the manufacturer’s instruc-
tion. Flow-cytometric analysis for induction of apoptosis
was performed as previously described [38].
Xenograft tumor radiosensitivity studies
Animal experiments were approved by Ethics Commit-
tee of Nanjing Medical University. Five to six week-old
male BALB/C nude mice were provided by Nanjing
Medical University Animal Center. A suspension of 1 × 106
Eca109 cells in 0.1 mL PBS was injected s.c. into one
site of the right leg of nude mice. Tumors were allowed
to grow for 7 days before treatment. Twenty-four nude
mice with established tumors (all ~250 mm3) were
divided into four groups and treated with (a) vehicle
(PBS) alone; (b) a single dose of 8 Gy IR; (c) YM155
alone (5 mg/kg as a 7-day continuous infusion); or
(d) YM155 plus IR (a single fraction of 8 Gy IR de-
livered on day 3 of drug treatment). Body weight
and tumor diameter were measured three times per
week, and tumor volume was determined according
to the formula: (length[L] × width[W]2)/2. The effi-
cacy of each treatment was evaluated by the volume
change during the treatment period. Growth delay
time (GD) was calculated as the time for treated tumors
to reach double in volume minus the time for control tu-
mors to reach double in volume. The enhancement factor
(EF) was then determined as follows: EF = (GDIR + YM155–
GDYM155)/GDIR. The first day of treatment was designated
as day 0, and observation continued until the day 20. At
the end of observation, mice were sacrificed and tumors
were fixed in 10% formalin, embedded in paraffin, and cut
into 5 μm-thick sections for immnohistochemistry (IHC)
and terminal deoxynucleotidyltransferase (dUTP) nick-
end labeling (TUNEL) assay.
Immunohistochemistry
Paraffin-embedded tumor tissue sections were deparaffi-
nized in xylene, rehydrated in graded ethanol, and rinsed
twice with PBS. Endogenous peroxidase activity was
blocked by incubating sections with 3% hydrogen peroxide
in the dark for 15 min. The sections were then incubated
overnight at 4°C with polyclonal antibody to survivin(1:50; Abcam, Ltd., Cambridge, United Kingdom) or
cleaved caspase-3 (1:100; Cell Signaling, Beverly, MA,
USA). After washes, slides were incubated with horserad-
ish peroxidase (HRP)-conjugated anti-rabbit secondary
antibody for 1 h at room temperature. Finally, the slides
were visualized by incubation with 3, 3′-diaminobenzidine
(DAB) (Dako, Hamburg, Germany) and counterstained
with hematoxylin (37%). The sections were analyzed
under a Zeiss Axiovert A1 light microscope. The intensity
for survivin immunoreactitity in tumor cells was evaluated
using Image-Pro Plus 6.0 software. Mean intensity was
calculated by dividing the integral optical density (IOD) by
area. The cleaved caspase-3 labeling index was calculated
by dividing the number of activated caspase-3-positive
cells by the total number of nuclei (per 1000 tumor cells
from four microscopic visual fields).
TUNEL assay
Paraffin-embedded tumor tissue were deparaffinized,
rehydrated and blocked in 3% hydrogen peroxide as
above. The slides were permeabilized with TritonX-100
in 0.1% sodium citrate for 10 min. TUNEL staining was
performed using the in situ cell death detection Kit-
POD (Roche Molecular Biology, Mannheim, Germany)
according to the manufacture’s protocol. Peroxidase ac-
tivity was visualized using the liquid DAB substrate
chromogen system (Dako), followed by a haematoxylin
counterstaining. The percentage of apoptosis was calcu-
lated by dividing the number of TUNEL-positive cells by
the total number of nuclei (per 1000 tumor cells from
four microscopic visual fields).
Statistical analysis
All data were expressed as the mean ± standard deviation
(SD). Statistical differences between groups were deter-
mined by the unpaired Student’s t test or one-factor
ANOVA. All statistical analysis was performed using SPSS
statistics 17.0 software (SPSS, Inc., Chicago, IL, USA). A P
value < 0.05 was considered statistically significant.
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